Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Camillo Porta, Chiara Paglino

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol- 3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/b-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers.

Original languageEnglish
Pages (from-to)103-113
Number of pages11
JournalWorld Journal of Hepatology
Volume2
Issue number3
DOIs
Publication statusPublished - 2010

Fingerprint

Hepatocellular Carcinoma
Aurora Kinases
Catenins
Retinoic Acid Receptors
Vascular Endothelial Growth Factor Receptor
Orphaned Children
Hepatocyte Growth Factor
Sirolimus
Phosphatidylinositols
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Phosphotransferases
Therapeutics
Biomarkers
Insulin
sorafenib
Neoplasms

ASJC Scopus subject areas

  • Hepatology

Cite this

Medical treatment of unresectable hepatocellular carcinoma : Going beyond sorafenib. / Porta, Camillo; Paglino, Chiara.

In: World Journal of Hepatology, Vol. 2, No. 3, 2010, p. 103-113.

Research output: Contribution to journalArticle

@article{c08cba4c0a724af0bbab0c152e1e2297,
title = "Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib",
abstract = "Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol- 3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/b-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers.",
author = "Camillo Porta and Chiara Paglino",
year = "2010",
doi = "10.4254/wjh.v2.i3.103",
language = "English",
volume = "2",
pages = "103--113",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group Co",
number = "3",

}

TY - JOUR

T1 - Medical treatment of unresectable hepatocellular carcinoma

T2 - Going beyond sorafenib

AU - Porta, Camillo

AU - Paglino, Chiara

PY - 2010

Y1 - 2010

N2 - Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol- 3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/b-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers.

AB - Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol- 3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/b-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=79955952335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955952335&partnerID=8YFLogxK

U2 - 10.4254/wjh.v2.i3.103

DO - 10.4254/wjh.v2.i3.103

M3 - Article

AN - SCOPUS:79955952335

VL - 2

SP - 103

EP - 113

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 3

ER -